Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“FDA approval for Dato-DXd is important, but TROPION-Breast01 deserves a critical look.
Yes, PFS improved — but with a modest absolute gain, no major OS breakthrough, and ongoing concerns about ILD, stomatitis, and ocular toxicity.
A valuable new option in HR+/HER2− metastatic breast cancer, though probably more ‘practice-changing’ than truly ‘game-changing.’ ”
